CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

07 Nov 2022 07:03:37 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

25 Oct 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

29 Sep 2022 10:18:17 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

09 Sep 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

24 Aug 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

09 Aug 2022 15:26:30 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

26 Jul 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

12 Jul 2022 05:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

17 May 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

10 May 2022 15:11:56 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

25 Apr 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

16 Mar 2022 15:20:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

11 Mar 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

08 Mar 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

03 Mar 2022 08:20:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

02 Mar 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

24 Feb 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

17 Feb 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

07 Feb 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

03 Feb 2022 07:03:00 By Nasdaq GlobeNewswire